ES2133324T3 - Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. - Google Patents

Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.

Info

Publication number
ES2133324T3
ES2133324T3 ES92914560T ES92914560T ES2133324T3 ES 2133324 T3 ES2133324 T3 ES 2133324T3 ES 92914560 T ES92914560 T ES 92914560T ES 92914560 T ES92914560 T ES 92914560T ES 2133324 T3 ES2133324 T3 ES 2133324T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
methods
formula
dibenzoxazepine compounds
substituted dibenzoxazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92914560T
Other languages
English (en)
Inventor
E Ann Hallinan
Timothy Joseph Hagen
Robert Knol Husa
Sofya Tsymbalov
Albert C Lee
Hoeck Jean-Pierre Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2133324T3 publication Critical patent/ES2133324T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Un procedimiento para preparar un compuesto que tiene la estructura **fórmula** o una sal farmacéuticamente aceptable del mismo; en donde: R1 es: halégeno; X es: -CH=CH-, -CF2-, -CHF-, -(CH2)n- o -(CH2)p-CH=CH-; en donde p y n son números enteros de 1 a 6; Y es: **fórmula**, azufre, **fórmula** u oxígeno; R3 es: hidrógeno o t-butiloxicarbonilo; Het es: piridilo, tienilo o furanilo; en donde m es un número enterode0 a 6; en donde q es el número entero 0 ó 1; caracterizado porque A) un aminoderivado de la fórmula **fórmula** en la que R1 es como se define anteriormente, se hace reaccionar con un cloruro de ácido dela fórmula Het-(CH2)m-(Y)(X)q-COCl en la que m, Y, X, q y Het son como se definen anteriormente, en presencia de una base o B) un aminoderivado de la fórmula **fórmula** en la que R1 es como se define anteriormente, se hace reaccionar con un éster de la fórmula Het-(CH2)m-Y-(X)q-COOMe/Et con m, Y, X, q y Het como se definen anteriormente, en presencia de un catalizador, o C) un aminoderivado de la fórmula **fórmula** en la que R1 es como se define anteriormente, se hace reaccionar con un ácido de la fórmula Het-(CH2)m-Y-(X)q-COOH con Het, m, Y, X, q como se definen anteriormente, en presencia de una amina, o D) un compuesto acetilado de la fórmula **fórmula** con R1 como se define anteriormente, se hace reaccionar con un aminocompuesto de la fórmula Het-(CH2)m-Y-(X)q-CONHNH2 con Het, m, Y, X, q como se definen anteriormente, en presencia de una base dando así los compuestos deseados que pueden convertirse de una manera conocida en compuestos en los que Y es SO o SO2 a través de la oxidación de un compuesto en el que Y = S, o en los enantiómeros respectivos, o las sales farmacéuticamente aceptables, de una manera conocida de por sí.
ES92914560T 1991-05-03 1992-04-16 Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. Expired - Lifetime ES2133324T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69565491A 1991-05-03 1991-05-03

Publications (1)

Publication Number Publication Date
ES2133324T3 true ES2133324T3 (es) 1999-09-16

Family

ID=24793923

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95116871T Expired - Lifetime ES2149305T3 (es) 1991-05-03 1992-04-16 Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.
ES92914560T Expired - Lifetime ES2133324T3 (es) 1991-05-03 1992-04-16 Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95116871T Expired - Lifetime ES2149305T3 (es) 1991-05-03 1992-04-16 Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y procedimientos de uso.

Country Status (12)

Country Link
EP (5) EP0583421B1 (es)
JP (1) JP3222891B2 (es)
AT (2) ATE194987T1 (es)
AU (1) AU2246292A (es)
CA (1) CA2108903C (es)
DE (2) DE69229442T2 (es)
DK (2) DK0694545T3 (es)
ES (2) ES2149305T3 (es)
GR (2) GR3030992T3 (es)
IE (2) IE921410A1 (es)
PT (2) PT911331E (es)
WO (1) WO1992019617A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5378840A (en) * 1992-04-16 1995-01-03 G. D. Searle & Co. Substituted dibenzoxazepine compounds
US5212169A (en) * 1991-10-31 1993-05-18 G. D. Searle & Co. Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
US5395932A (en) * 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5354746A (en) * 1993-06-01 1994-10-11 G. D. Searle & Co. Squaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5354747A (en) * 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5461047A (en) * 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5424424A (en) * 1993-10-07 1995-06-13 G. D. Searle & Co. Tartaric acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5488046A (en) * 1993-11-03 1996-01-30 G. D. Searle & Co. Carbamic acid derivatives of substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5449675A (en) * 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
US5441950A (en) * 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
JP4175113B2 (ja) * 2001-03-14 2008-11-05 小野薬品工業株式会社 Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤
US20060100195A1 (en) * 2001-11-19 2006-05-11 Takayuki Maruyama Remedies for urinary frequency
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US9181187B2 (en) 2007-02-16 2015-11-10 Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3624104A (en) * 1969-10-27 1971-11-30 Searle & Co Aralkanoyl derivatives of dibenzoxazepine-n-carboxylic acid hydrazides
US3917649A (en) * 1971-03-23 1975-11-04 Searle & Co Dibenzoxazepine N-carboxylic acid hydrazides and derivatives
GB1522003A (en) * 1975-10-17 1978-08-23 Searle & Co 1-acyl-2-(8-chloro-10,11-dihydrodibenz-(b,f)(1,4)-oxazepine-10-carbonyl)hydrazines
US4045442A (en) * 1976-01-05 1977-08-30 G. D. Searle & Co. 1-(Substituted amino)alkanoyl-2-(dibenzoxazepine-10-carbonyl)hydrazines and derivatives thereof
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides

Also Published As

Publication number Publication date
EP0694546A3 (en) 1996-03-27
PT694546E (pt) 2001-09-28
IE20000774A1 (en) 2001-02-21
EP0583421A1 (en) 1994-02-23
EP0911331B1 (en) 2003-10-22
EP0911331A3 (en) 2000-01-19
JP3222891B2 (ja) 2001-10-29
WO1992019617A3 (en) 1992-12-10
DE69229442D1 (de) 1999-07-22
CA2108903A1 (en) 1992-11-04
DK0694545T3 (da) 2000-09-18
GR3030992T3 (en) 1999-12-31
JPH06507408A (ja) 1994-08-25
ES2149305T3 (es) 2000-11-01
IE921410A1 (en) 1992-11-04
EP0694545A3 (en) 1996-03-27
CA2108903C (en) 2004-02-10
EP0694546A2 (en) 1996-01-31
DE69231298T2 (de) 2001-01-18
EP0694545A2 (en) 1996-01-31
ATE181329T1 (de) 1999-07-15
WO1992019617A2 (en) 1992-11-12
ATE194987T1 (de) 2000-08-15
GR3034650T3 (en) 2001-01-31
DE69231298D1 (de) 2000-08-31
PT911331E (pt) 2004-03-31
DK0583421T3 (da) 1999-11-22
EP0512400B1 (en) 1998-12-02
DE69229442T2 (de) 1999-10-28
EP0694546B1 (en) 2001-06-06
EP0583421B1 (en) 1999-06-16
EP0911331A2 (en) 1999-04-28
EP0512400A1 (en) 1992-11-11
AU2246292A (en) 1992-12-21
EP0694545B1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
BR0109703A (pt) Derivados de piperazina
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
FI923664A (fi) Piperidinderivat
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
ES2092645T3 (es) Metanoantracenos como antagonistas de dopamina.
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 583421

Country of ref document: ES